Trial Profile
A Multi-Center, Open Label, Non-Randomized, Phase II Study to Assess the Activity and Safety of Cetuximab Plus Irinotecan in Subjects With EGFR-Detectable Metastatic Colorectal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 17 Nov 2006 New trial record.